Innovations • Global Impact • In The News • Our People

AAHI's Approach to Next-Generation COVID Vaccines

Our unique immune-enhancing adjuvant and RNA platform technologies are supporting Covid vaccines for longer lasting, broadly protective immunity that can be given by nasal spray to prevent continued transmission.


The latest scientific breakthroughs at AAHI.

Make your products accessible to those who need them most. Collaborate with AAHI.



Collaboration across communities. Explore AAHI's different areas of impact.

San Antonio, USA

Diversifying the Next Generation of Tuberculosis Vaccines

AAHI partners with Texas Biomed to explore novel adjuvant technology, mix-and-match protein and RNA vaccine regimens, and nasal spray vaccines to protect against TB using preclinical models designed to reflect the genetic diversity in the human population. 

Bangkok, Thailand

Phase 1 Clinical Trial of Adjuvanted Plant Based Protein COVID-19 Vaccine

Baiya Phytopharm announces preliminary results of trials showing its plant-based SARS-CoV-2 vaccine candidate containing AAHI's 3M-052-AF/Alum adjuvant formulation is safe in humans.

Seattle, USA

Adjuvanted HIV Vaccine Clinically Evaluated with New Germline-Targeting Approach

A new germline-targeting antigen is expected to elicit a particular class of broadly neutralizing antibodies that protect from viral mutations when paired with AAHI's 3M-052-AF adjuvant formulation. Phase 1 clinical trials commenced over the summer in our own backyard. 

Help us make impossible vaccines possible.


By Allison Gatlin

Investor's Business Daily

"The virus always wins. The virus is always a few steps ahead of us. Any vaccine strategy that requires us to catch up means we're always going to be behind," Dr. Corey Casper, Chief Executive Officer, shares his thoughts about developing viral threats. He highlights the importance of continued investment in the development of a next-generation vaccine that can protect against all coronaviruses - a "pan" vaccine.

By Gail Dutton

Genetic Engineering & Biotechnology News

AAHI's Senior Vice President, Formulations, Christopher Fox, PhD, discusses several approaches to simplifying manufacturing processes for RNA and protein vaccines and enable equitable access to life-saving health solutions in low- and middle-income countries. 


Collaboration across communities. Explore our different areas of impact.

Featured Post

November 8-10 | Boston Park Plaza Hotel

AAHI's scientists are presenting novel applications of our RNA vaccine platform at the 10th International mRNA Conference, a premier meeting for industry and academic professionals to explore the rapidly advancing science and business of mRNA medicines.

Openings and Opportunities


The Senior Scientist joining our RNA vaccine team will be responsible for broadening the applications of
AAHI's RNA vaccine platform to a wide range of infectious disease and oncology targets.

Operations/Project Management

The Sponsored Research Administrator will provide sponsored support for research awards, product development contracts, and other funded projects while also playing a key role in the creation, budgeting, and submission of grant and contract applications.

Learn more about our formulation technology

We partner with biotech leaders to develop vaccines and more.

Synthetic TLR4 ligand in squalene nanoemulsion

Synthetic TLR4 ligand in QS- 21 containing liposome

Synthetic TLR4 ligand in aqueous formulation

Dual agonist containing both TLR4 and TLR7/8 ligands

2nd-Gen synthetic TLR4 ligand
in squalene nanoemulsion

2nd-Gen synthetic TLR4 ligand
in QS-21 containing liposome

2nd-Gen synthetic TLR4 ligand
in aqueous formulation

Alum nanoparticle formulation, customized particle size

Synthetic TLR7/8 ligand in
squalene nanoemulsion

Synthetic TLR7/8 ligand
adsorbed to aluminum

Synthetic TLR7/8 ligand in
aqueous formulation

Nanostructured lipid carrier

See how our formulations are being used.

Follow AAHI

Sign up to stay in touch!

Get the latest news and updates in your inbox every month and learn more about how our scientists are developing equitably accessible vaccines and therapeutics for people who most need them.